Flow Cytometry catalog - ROW 2019

ClearLLab Antibody Solutions

The ClearLLab reagents are intended for in vitro diagnostic use as a screening panel for identification of various cell populations by immunophenotyping on an FC 500 flow cytometer. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having hematopoietic neoplasia including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS), and/or myeloproliferative neoplasms (MPN). The reagents can be used with peripheral whole blood (collected in K2EDTA, ACD or Heparin), bone marrow (collected in K2EDTA, ACD or Heparin) and lymph node specimens for immunophenotyping. The results should be interpreted along with additional clinical and laboratory findings. These reagents provide qualitative results for the parameters listed below:

- ClearLLab M: CD7, CD13, CD34, CD33, CD45 - ClearLLab T1: CD2, CD56, CD7, CD5, CD45 - ClearLLab T2: CD8, CD4, CD3, CD45

- ClearLLab B1: Kappa, Lambda, CD19, CD5, CD45 - ClearLLab B2: CD20, CD10, CD19, CD38, CD45

• CE marked and FDA cleared: Minimize your lab’s validation work. • Enhanced workflow: No manual antibody cocktail preparation.

• Consensus aligned: Ensures you work according to international guidelines. • Small kit size: Adapt your inventory to actual demand with the 25 tests/vial. • Versatile: ClearLLab can be used with peripheral blood, bone marrow and lymph node specimens. • Identify major cell populations with ClearLLab’s 5-combination, 18-marker panels. A casebook has been designed to present examples of flow cytometric immunophenotyping data and analysis using Beckman Coulter’s ClearLLab reagents on the Beckman Coulter FC 500 flow cytometer. Cases with characteristic findings typical of various lymphoid and myeloid neoplasms are included, as are cases from patients with clinical and/or laboratory findings that suggest an underlying neoplastic process, but in which no immunophenotypic abnormality is identified. Specimen types include peripheral blood, bone marrow, and lymph nodes. Each case includes a clinical vignette that describes the patient demographics and clinical history, case specific listmode data files for reanalysis by the user of this casebook, ClearLLab-specific analysis protocols to be used with the listmode data, and a report showing the analysis with provided protocols. Each case concludes with an Analysis Notes section that highlights the immunophenotypic findings as well as potential pitfalls. NOTE: Casebook examples are provided for illustrative purposes only, and not all categories of hematolymphoid neoplasms may be represented, nor are all possible immunophenotypic variants described or demonstrated.

ClearLLab B1

k Chain-FITC/ λ Chain-PE/CD19-ECD/CD5-PC5.5/CD45-PC7

Clone

Kappa-FITC Lambda-PE CD19-ECD CD5-PC5.5 CD45-PC7 Combination

Isotype

Polyclonal

F(ab’) 2 F(ab’) 2

(rabbit)

Examples of dual parameter histograms from a mature B- cell neoplasm sample for ClearLLab B1 and B2 reagents. Note: not all histograms shown.

Polyclonal

(rabbit)

J3-119

IgG1 (mouse)

BL1a

IgG2a (mouse)

J33

IgG1 (mouse)

Format

Line

Status

Size

Part #

25 tests

Liquid

ClearLLab

IVD & CE

B66809

ClearLLab B2

CD20-FITC/CD10-PE/CD19-ECD/CD38-PC5.5/CD45-PC7

Clone

CD20-FITC Combination

Isotype

B9E9

IgG2a (mouse)

CD10-PE

ALB1

IgG1 (mouse)

CD19-ECD

J3-119

IgG1 (mouse)

CD38-PC5.5 CD45-PC7

LS198-4-3

IgG1 (mouse)

J33

IgG1 (mouse)

Format

Line

Status

Size

Part #

25 tests

Liquid

ClearLLab

IVD & CE

B66810

ANTIBODIES & KITS

187

Outside US Flow Cytometry Catalog